SCHEMBL4775262

SCHEMBL4775262

O=C(OCc1ccccc1)c1ccc(NS(=O)(=O)CCc2cccc(Cl)c2Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
RAB9A P51151 5/20 0.47
KMT2A Q03164 5/20 0.46
GAA P10253 1/20 0.46
LMNA P02545 2/20 0.45
NPC1 O15118 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HSP90AA1 P07900 1/20 0.43
HPGD P15428 3/20 0.42
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 3/20 0.41
THRB P10828 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
IKBKB O14920 1/20 0.39
AR P10275 2/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767922 0.83 KDM4E (0.38) MAPTRAB9AKMT2ANPC1HPGD
SCHEMBL4775200 0.82 L3MBTL1 (0.47) MAPTLMNATDP1HPGDALDH1A1
SCHEMBL4776450 0.81 STAT3 (0.44) MAPTRAB9ALMNANPC1HPGD
SCHEMBL4774741 0.78 HPGD (0.58) MAPTRAB9AKMT2ALMNANPC1
SCHEMBL4770885 0.77 SMN1; SMN2 (0.50) RAB9AKMT2ANPC1ALDH1A1SMN1; SMN2
SCHEMBL4773300 0.76 CA1 (0.47) KMT2AGAALMNAHPGDALDH1A1
SCHEMBL4773260 0.76 L3MBTL1 (0.44) KMT2ASLC6A2ALDH1A1
SCHEMBL15754261 0.76 HPGD (0.55) MAPTRAB9AKMT2AGAALMNA
SCHEMBL4778522 0.76 ALDH1A1 (0.46) KMT2AGAALMNANPC1ALDH1A1
SCHEMBL4773056 0.76 ALDH1A1 (0.46) KMT2AGAALMNANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 MAPT 294/4885RAB9A 1213/4885KMT2A 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.